Media stories about vTv Therapeutics (NASDAQ:VTVT) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. vTv Therapeutics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.1304544733714 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
VTVT has been the subject of several analyst reports. Zacks Investment Research downgraded shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a research note on Wednesday, July 5th. HC Wainwright set a $13.00 price objective on shares of vTv Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 4th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $15.00 price objective on shares of vTv Therapeutics in a research report on Friday, August 4th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. vTv Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $14.50.
Shares of vTv Therapeutics (VTVT) opened at 7.10 on Friday. The stock’s 50 day moving average is $6.02 and its 200 day moving average is $6.02. vTv Therapeutics has a 52-week low of $3.57 and a 52-week high of $7.28. The firm’s market capitalization is $68.82 million.
vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.41) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.02. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.19 million. On average, equities research analysts forecast that vTv Therapeutics will post ($1.06) EPS for the current year.
In other news, major shareholder Ronald O. Perelman purchased 50,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was bought at an average cost of $4.72 per share, for a total transaction of $236,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ronald O. Perelman purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were purchased at an average price of $4.97 per share, with a total value of $49,700.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 165,000 shares of company stock valued at $728,150 over the last quarter. 0.80% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.thestockobserver.com/2017/10/13/vtv-therapeutics-vtvt-earning-somewhat-positive-news-coverage-accern-reports.html.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.